M&A Deal Summary

Hyperion Therapeutics Acquires Andromeda Biotech

On June 12, 2014, Hyperion Therapeutics acquired life science company Andromeda Biotech for 13M USD

Acquisition Highlights
  • This is Hyperion Therapeutics’ 1st transaction in the Life Science sector.
  • This is Hyperion Therapeutics’ largest (disclosed) transaction.
  • This is Hyperion Therapeutics’ 1st transaction in Israel.

M&A Deal Summary
Date 2014-06-12
Target Andromeda Biotech
Sector Life Science
Buyer(s) Hyperion Therapeutics
Deal Type Add-on Acquisition
Deal Value 13M USD

Target

Andromeda Biotech

Yavne, Israel
Andromeda Biotech Ltd. is a biopharmaceutical company.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Hyperion Therapeutics

Brisbane, California, United States
Category Company
Founded 2006
Sector Life Science
DESCRIPTION

Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Israel) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal